Jardiance Gets Heart Failure Nod, But How Long Will Its Reign Last?

The SGLT2 inhibitor has better efficacy and clearer labeling than Novartis’s Entresto in heart failure with preserved ejection fraction, but AstraZeneca’s Farxiga is expected to produce Phase III data by June.

3D rendering of the Heart valve
Eli Lilly and Boehringer Ingelheim's Jardiance received FDA approval for heart failure with preserved ejection fraction • Source: Shutterstock

The new label expansion for Eli Lilly and Company/Boehringer Ingelheim GmbH’s SGLT2 inhibitor Jardiance (empagliflozin) for heart failure with preserved left ventricular ejection fraction (HFpEF) gives it a significant edge in the space given its superior efficacy and more clearly defined labeling compared with Novartis AG’s heart failure drug Entresto. However, the potential success of another competitor in the SGLT2 inhibitor class could make its reign short-lived.

The US Food and Drug Administration approved Jardiance for HFpEF on 24 February, six months after the agency gave it...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from New Products

More from Scrip